Anne Bramman
Analyst · Adam Josephson with KeyBanc Capital Markets
Thanks, Dean, and hello, everyone. I will supplement Dean's commentary with some color on the financial results for the company and segments.
In Q2, the company delivered a 14% increase in adjusted earnings per share on 4% organic sales growth. Currency translation reduced reported sales by 9.5% with an approximately $0.10 impact to EPS.
Adjusted operating margins in the second quarter improved 140 basis points to 9.5% as the benefit of productivity initiatives, higher volumes and the net impact of price and raw material input cost more than offset higher employee-related expenses. The company realized about $18 million of incremental savings from restructuring costs net of transition expenses.
The adjusted tax rate was 34%, consistent with the anticipated full-year tax rate in the low to mid-30% range.
Free cash flow was $130 million, an increase of $45 million compared to Q2 of last year, driven by improved working capital productivity and higher earnings.
In the first half, the company repurchased approximately 1.1 million shares at a cost of $62 million and paid $66 million in dividends. As Dean indicated, we are committed to returning cash to shareholders and have sufficient capacity to continue our share buyback program. Consistent with our stated philosophy and strategy, we continue to be disciplined and opportunistic with share repurchases buying relatively more when the share price dips and relatively less when the share price is higher.
Now looking at the segments. Pressure-sensitive Materials sales were up approximately 6% on an organic basis. Label and Packaging Materials sales were up mid-single-digits as were the combined sales for Performance Tapes and Graphics.
On a regional basis, North America delivered another quarter of low digit -- low single-digit growth, while Western Europe was up high single digits, benefiting from above-average growth in Graphics and continued strength in products for labeling applications. Organic growth for emerging regions improved compared to the first quarter, but continued to be relatively slow up mid-single digits due to softness in China as Dean mentioned.
PSM's adjusted operating margin, a record 12.3% for the segment, was up over 2 full points compared to last year. This improvement was driven by productivity, included continuing material for engineering savings and our recently increased level of restructuring activities, as well as fixed cost leverage through strong volume growth. We also saw a net benefit from price and raw material input costs as we continue to reinforce our pricing discipline, particularly in the less-differentiated segments of the market.
Both North America and Europe continued to experience benefits from product mix as both regions had faster growth in higher-margin segments.
Sequentially, adjusted operating margin for PSM expanded by 80 basis points, primarily due to incremental savings from restructuring and other productivity initiatives.
The Retail Branding Information Solutions sales declined approximately 2% on an organic basis and adjustment operating margin contracted by 40 basis points. Several factors contributed to the organic sales decline in the quarter. Once again, with sales up high single digits, we saw growth in performance segments for both Europe- and North America-based retailers and brand owners. However, we continue to experience declines in the value and contemporary segments, reflecting the share loss that we've been speaking to over the last few quarters. Additionally, sales of apparel labels for Europe-based retailers and brand owners were further impacted by reduced orders for apparels due to the impact of the euro devaluation on the cost of imported goods.
As expected, sales for RFID products declined due to reduced demand from a couple of large European accounts. However, as Dean mentioned, sales in the second half are expected to grow in the mid-30% range.
Returning to the total segment, the decline in adjusted operating margin reflects the impact of the lower sales, including reduced fixed cost leverage and negative price and mix, as well as higher employee-related costs. These challenges were partially offset by the benefit of productivity initiatives.
We are focused on reducing costs and streamlining our processes to position ourselves to grow and win in all the segments.
Sales in Vancive Medical Technologies declined about 1% on an organic basis, following an 11% increase in the first quarter. Given the application-specific nature of orders in this business, we do expect sales growth to be somewhat choppy by quarter. We continue to anticipate that organic sales growth for Vancive will be faster than the company average for the full year. The segment's operating loss was reduced by nearly $1 million due to productivity actions. The team continues to focus on the milestones needed to drive long-term growth of this platform with the objective of achieving a positive contribution to earnings by year-end.
Turning now to our outlook for the full year, we've raised our estimates of organic sales growth modestly to a range of 3.5% to 4%, reflecting the strength of PSM in the first half.
We have maintained our adjusted EPS guidance, as we believe that out-performance by PSM will offset the combined negative impacts of weaker-than-planned performance by RBIS and a higher-than-expected share count.
We outlined some of the key contributing factors to this guidance on Slide 8 of our supplemental presentation materials. Several of the assumptions underlying our previous guidance have changed modestly. Specifically, for the full year, at recent exchange rates, we estimate that currency translation will reduce net sales by approximately 8%, a slight improvement from the rates in April.
Our outlook for the impact of currency translation on pretax earnings and EPS have not changed. As discussed, we now estimate average shares outstanding on a fully diluted basis will be in the range of 92 million to 93 million shares. We divested a small, roughly breakeven industrial printer product line in Europe during that second quarter, which resulted in the recognition of a loss and some related exit cost. We've included the loss and associated cost in our pro forma adjustment for the quarter, [indiscernible] our estimate for restructuring cost and other items by $0.03 to $0.43 per share. As a result, while our guidance for adjusted EPS remains unchanged, we have reduced our estimate for reported EPS by $0.03.
Summing up, we delivered another good quarter and remain on track to achieve our 2015 and 2018 targets. Now we'll open the call up for your questions.